Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
118 hedge funds and large institutions have $602M invested in Adamas Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 46 increasing their positions, 26 reducing their positions, and 32 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 26
20% more call options, than puts
Call options by funds: $7.01M | Put options by funds: $5.86M
3% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 32
1% more funds holding
Funds holding: 117 → 118 (+1)
14% less capital invested
Capital invested by funds: $702M → $602M (-$100M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$45.4M |
| 2 |
BC
Broadfin Capital
New York
|
+$35.8M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$29M |
| 4 |
PA
Perceptive Advisors
New York
|
+$19.9M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$18.1M |
| 2 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$15.2M |
| 3 |
BWCA
Brenner West Capital Advisors
New York
|
-$10.2M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$10M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$8.62M |
ADMS Hedge Fund Activity: Q1 2018 in Review
118 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q1 2018, worth a combined $602M — down 14% from $702M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ADMS positions and 32 closed out — a net gain of 1 holder — while 46 added to existing stakes and 26 trimmed.
The largest buyer was State Street, adding an estimated $45.4M. The largest seller was Millennium Management, cutting an estimated $18.1M.
- 118 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q1 2018, up from 117 in Q4 2017.
- Funds reported $602M of Adamas Pharmaceuticals stock for Q1 2018, down 14% quarter-over-quarter.
- 33 funds opened new Adamas Pharmaceuticals positions in Q1 2018 and 32 closed out, a net change of +1 holder.
- The largest Adamas Pharmaceuticals buyer in Q1 2018 was State Street, an estimated $45.4M added.
- The largest Adamas Pharmaceuticals seller in Q1 2018 was Millennium Management, an estimated $18.1M sold.
Based on aggregated 13F filings for Q1 2018.